As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed – FierceBiotech
FierceBiotech |
As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed
FierceBiotech The FDA 'breakthrough' tagged Juliet data, which many have been waiting for to see how well it could stack up against rival Kite Pharma, was assessing CTL019 (a.k.a tisagenlecleucel) in 51 relapsing/remitting diffuse large B-cell lymphoma (r/r DLBCL) … Novartis touts new T–cell therapy data in race for FDA approval Novartis' CAR–T stacks up to Kite in lymphoma Novartis' posts landmark CAR–T data as head-to-head rivalry with Kite Pharma looms |
